September 21, 2023, NEW YORK - A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer. Researchers led by Ludwig Lausanne's Sara Bobisse, Alexandre Harari , Lana Kandalaft and Director George Coukos analyzed responses to the combination therapy of 18 patients with advanced ovarian cancer who had previously participated in a clinical trial evaluating a therapeutic regimen that incorporated the personalized cancer vaccine.
https://www.miragenews.com/personalized-vaccine-and-t-cell-therapy-aid-1089569/#miragenews
Sinun täytyy kirjautua sisään ennen kuin voit kommentoida.